{
    "clinical_study": {
        "@rank": "162977", 
        "arm_group": [
            {
                "arm_group_label": "Individual dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Fixed dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to induce normal pubertal\n      development in girls with Turner Syndrome in accordance with that of their peers and their\n      individual state psychosocial maturation."
        }, 
        "brief_title": "Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome", 
        "completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Genetic Disorder", 
            "Turner Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Genetic Diseases, Inborn", 
                "Turner Syndrome", 
                "Gonadal Dysgenesis", 
                "Primary Ovarian Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Turner Syndrome\n\n          -  Treatment with growth hormone\n\n          -  Bone age minimum 12 years and maximum 14 years\n\n          -  Clear signs of ovarian insufficiency\n\n          -  Well documented growth rate during the last 12 months\n\n        Exclusion Criteria:\n\n          -  Signs of spontaneous puberty\n\n          -  Known or suspected hypersensitivity to trial product\n\n          -  Acute or chronic liver disease\n\n          -  Previous treatment with estrogen\n\n          -  Undiagnosed abnormal genital bleeding\n\n          -  Known thyroid diseases not adeadequately treated\n\n          -  Porphyria"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710696", 
            "org_study_id": "GHTUR/E/2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Individual dose", 
                "description": "5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally", 
                "intervention_name": "17-beta estradiol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fixed dose", 
                "description": "0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally", 
                "intervention_name": "17-beta estradiol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 19, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "number_of_arms": "2", 
        "official_title": "Induction of Puberty With 17-Beta Estradiol in Girls With Turner Syndrome. An Open Randomized Trial", 
        "overall_official": {
            "affiliation": "Novo Nordisk Pharma SA", 
            "last_name": "Fernando Fuentes", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pubertal stage assesed by Tanner score", 
                "safety_issue": "No"
            }, 
            {
                "measure": "FSH (Follicle Stimulating Hormone) levels", 
                "safety_issue": "No"
            }
        ], 
        "removed_countries": {
            "country": "Spain"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710696"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Height velocity", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Pubertal stage assessed by Tanner score: Breast, pubic hair, axillary hair", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 1998", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}